Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesotheliomaIrene Dell’Anno(University of Pisa), Stefano Landi(University of Pisa)Investigational New DrugsDecember 9, 202010.1007/s10637-020-01040-yCited by 12SaveCiteExport RISWatch citationsRelated PapersBAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma|Cancer Gene Therapy|2024|2Thonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling|Cancer Cell International|2024|1